Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01306890 · ClinicalTrials.gov registry record
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
A clinical trial, sponsored by Dendreon.
- Completed
- Registry status
- 1,976
- Enrollment target
NCT01306890: Completed study, sponsored by Dendreon.
NCT01306890 is a clinical trial that has completed, run by Dendreon. The registered enrollment target is 1,976 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01306890 has completed, sponsored by Dendreon.
- COMPLETED
- Registry status
- 1,976 participants
- Enrollment target
Study Summary
The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.
Primary Outcome
The incidence rate of CVEs (cardiovascular events) was estimated as the number of new events per 100 patient years of follow-up in the overall sample of men with advanced-stage or metastatic prostate cancer and in men with or without castration.
Interventions
- BIOLOGICAL sipuleucel-T
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,976 participants |
| Start Date | 2011-01-27 |
| Est. Completion | 2017-01-17 |
What the finished NCT01306890 record still lists
NCT01306890 is an observational study that tracks outcomes without assigning an intervention. Its 1,976 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which sipuleucel-T is the first listed.
NCT01306890 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01306890 about?
NCT01306890 is a clinical study titled "A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer". The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.
What is the current status of trial NCT01306890?
This trial is currently completed. The enrollment target is 1,976 participants. The study started on 2011-01-27. Estimated completion is 2017-01-17.
What interventions are being tested in trial NCT01306890?
The interventions under investigation include: sipuleucel-T (BIOLOGICAL).
Who is sponsoring clinical trial NCT01306890?
This trial is sponsored by Dendreon, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06062394 · 1,980 participants · NA
Penn Medicine Healthy Heart
- NCT07321886 · 1,980 participants · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- NCT04251052 · 1,956 participants · NA
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI